Veterinary Pharmaceutical Suspensions: Formulation Approaches, Stability, And Therapeutic Applications

Veterinary oral and injectable¹ suspensions constitute one of the most widely employed pharmaceutical dosage forms for the treatment, prevention, and management of diseases in companion animals, livestock, poultry, aquaculture species, and wildlife. These formulations are particularly valuable for drugs with poor aqueous solubility because they enable improved drug dispersion, flexible dosing, enhanced bioavailability, and prolonged therapeutic activity. Oral suspensions² facilitate accurate dose adjustment across animals of different body weights and ages, while injectable suspensions³ provide sustained drug release, reduced dosing frequency, and improved treatment compliance, particularly in food-producing animals where repeated handling is undesirable.

Unlike human pharmaceutical products, veterinary formulations must accommodate considerable interspecies differences in anatomy, gastrointestinal physiology, metabolism, feeding behaviour, and management practices. These biological variations profoundly influence drug absorption, distribution, metabolism, elimination, and therapeutic response⁴. Consequently, formulation approaches that are effective in one species may not be suitable for another. For example, ruminants require rumen-bypass or depot delivery systems to protect susceptible drugs from microbial degradation within the rumen. Horses require highly palatable and taste-masked oral suspensions because of their sensitivity to unpleasant flavours, whereas dogs and cats’ benefit from concentrated, small-volume formulations that improve owner compliance. In contrast, poultry and aquaculture industries rely heavily on suspensions that remain physically stable during mass medication through drinking water or feed while maintaining uniform drug distribution and minimizing environmental contamination⁵.

Despite their widespread therapeutic applications, veterinary suspensions present several formulation challenges. Physical instability, including sedimentation, flocculation, crystal growth, and caking, can compromise dose uniformity and reduce therapeutic efficacy. Chemical degradation resulting from hydrolysis, oxidation, photodegradation, or excipient incompatibility further limits product stability, particularly under tropical climates and field storage conditions. Injectable suspensions additionally require optimal syringeability, redispersibility, sterility, and controlled rheological properties to ensure safe and reproducible administration. These challenges necessitate careful selection of excipients, optimization of particle size, viscosity control, and implementation of robust stability-enhancing strategies throughout product development⁶.

The therapeutic applications of veterinary suspensions extend across numerous drug classes, including antibiotics⁷, antiparasitic agents⁸, non-steroidal anti-inflammatory drugs⁹ (NSAIDs), corticosteroids, antifungal agents, vaccines, hormones, and nutraceuticals. Each therapeutic category presents unique formulation requirements that influence drug release characteristics, pharmacokinetic behaviour, palatability, and long-term stability. Advances in pharmaceutical technology, including nanosuspensions, nanostructured lipid carriers, solid lipid nanoparticles, liposomes, biodegradable polymeric depots, and lipid-based delivery systems, have significantly expanded opportunities for improving the efficacy, safety, and convenience of veterinary suspension formulations.

Although numerous studies have addressed individual aspects of veterinary suspension technology, the available literature remains fragmented, with limited integration of formulation principles, species-specific considerations, therapeutic applications, and emerging drug delivery technologies. A comprehensive synthesis of these interconnected aspects is essential for guiding future formulation development and improving veterinary pharmaceutical practice.

Therefore, this review provides a comprehensive and up-to-date overview of veterinary oral and injectable suspensions, with particular emphasis on formulation strategies, excipient selection, particle engineering, therapeutic class applications, stability challenges, species-specific requirements, and recent technological innovations. In addition, future perspectives involving nanotechnology, sustainable excipients, controlled-release systems, and species-specific clinical trial integration are discussed to highlight emerging directions for the development of next-generation veterinary suspension formulations.

1. Formulation Principles of Veterinary Suspensions

The successful development of veterinary oral and injectable suspensions depends on a comprehensive understanding of physicochemical properties, species-specific physiological differences, therapeutic objectives, and practical administration requirements. Unlike conventional human formulations, veterinary suspensions must accommodate a broad range of animal species with substantial variations in gastrointestinal physiology, metabolic activity, body size, feeding behaviour, and management practices. Consequently, formulation design extends beyond ensuring pharmaceutical stability to include palatability, dosing accuracy, ease of administration, storage stability, and field applicability.

An ideal veterinary suspension should exhibit uniform drug distribution, minimal sedimentation, excellent redispersibility, appropriate viscosity, chemical stability throughout its shelf life, and acceptable sensory characteristics for the target species. Injectable suspensions must additionally possess optimal syringeability, sterility, controlled drug release, and minimal injection-site irritation. Achieving these objectives requires careful selection of excipients, optimization of particle size, and formulation strategies tailored to the intended animal species and therapeutic indication¹⁰.

2. Selection of Excipients

Excipients play a critical role in determining the quality, stability, safety, and therapeutic performance of veterinary suspensions. Appropriate excipient selection ensures uniform particle dispersion, minimizes sedimentation, prevents caking, and maintains consistent dosing throughout storage and administration¹¹.

Suspending agents such as sodium carboxymethyl cellulose (CMC), hydroxypropyl methylcellulose (HPMC), methylcellulose, xanthan gum, guar gum, tragacanth, and sodium alginate are commonly incorporated to increase viscosity and reduce particle settling. These polymers improve physical stability while maintaining acceptable flow properties during administration¹².

Wetting agents facilitate uniform dispersion of hydrophobic drug particles by reducing interfacial tension between the drug and the aqueous vehicle. Non-ionic surfactants, including polysorbates (Tween series) and sorbitan esters (Span series), are widely employed because of their favorable safety profile and compatibility with a broad range of active pharmaceutical ingredients (APIs)¹³.

Flocculating agents regulate particle interactions to produce loosely aggregated flocs that redisperse easily upon gentle shaking, thereby minimizing hard caking during storage. Electrolytes, polymers, and surfactants may be used individually or in combination to achieve controlled flocculation¹⁴.

Additional excipients, including preservatives, antioxidants, buffering agents, viscosity modifiers, sweeteners, flavoring agents, and coloring agents-are incorporated according to the intended route of administration. Oral veterinary suspensions frequently require species-specific flavoring agents to improve acceptance. Meat- or poultry-based flavors are generally preferred by dogs, fish flavors by cats, and molasses or apple flavors by horses. Conversely, injectable suspensions prioritize sterility, biocompatibility, isotonicity, and compatibility with parenteral administration over sensory attributes.

2.1 Particle Size and Advanced Suspension Technologies

Particle size is one of the most influential formulation variables affecting dissolution rate, bioavailability, sedimentation behavior, syringeability, and overall therapeutic performance of veterinary suspensions. According to the Noyes-Whitney relationship, decreasing particle size increases surface area, thereby accelerating drug dissolution and improving absorption, particularly for poorly water-soluble compounds¹⁵.

Micronization remains a widely used approach for improving dissolution while maintaining acceptable physical stability. However, recent advances in pharmaceutical engineering have led to the development of nanosuspensions and microsuspensions, which provide substantially greater surface area, enhanced saturation solubility, improved oral bioavailability, and more consistent therapeutic outcomes¹⁶.

Nanocrystal-based formulations have demonstrated considerable promise for veterinary medicines with poor aqueous solubility by improving dissolution kinetics and reducing dose variability. Similarly, lipid-based carriers, polymeric nanoparticles, liposomes, nanoemulsions, and nanostructured lipid carriers (NLCs) further enhance drug stability, prolong systemic exposure, and facilitate controlled drug release¹⁷.

The choice of suspension vehicle also influences formulation performance. Aqueous suspensions are generally preferred for oral administration because they provide good palatability, convenient dosing, and ease of manufacture. In contrast, oil-based injectable suspensions offer improved chemical stability and prolonged drug release, making them particularly suitable for depot formulations used in livestock production.

Advances in particle engineering, including high-pressure homogenization, wet milling, spray drying, and antisolvent precipitation, have significantly improved control over particle size distribution, redispersibility, and suspension stability. These technologies enable the development of veterinary formulations with improved pharmacokinetic performance and enhanced therapeutic efficacy across diverse animal species.

2.2 Species-Specific Formulation Considerations

Species-specific physiological and behavioral characteristics represent one of the defining aspects of veterinary pharmaceutical development. Formulations must therefore be designed to accommodate differences in gastrointestinal anatomy, feeding behavior, metabolism, body size, and methods of drug administration.

In ruminants, orally administered drugs may undergo microbial degradation within the rumen before systemic absorption. Consequently, rumen-bypass technologies, enteric coatings, lipid encapsulation, and depot injectable formulations are frequently employed to preserve drug integrity and enhance bioavailability¹⁸.

Horses are particularly sensitive to unpleasant taste and texture, necessitating effective taste-masking strategies using flavoring agents, sweeteners, and microencapsulation techniques. Oral suspensions should also possess appropriate viscosity to facilitate administration through dosing syringes while minimizing drug spillage¹⁹.

Companion animals such as dogs and cats require highly palatable, concentrated, and low-volume formulations that improve owner compliance and reduce administration-related stress. Accurate dose measurement, prolonged physical stability, and minimal shaking requirements further enhance treatment adherence²⁰.

Poultry and aquaculture species present unique challenges because medications are commonly administered to entire populations through feed or drinking water. Consequently, suspensions must exhibit excellent dispersibility, resistance to sedimentation, stability across varying water quality conditions, and compatibility with large-scale delivery systems. Environmental considerations, including minimization of drug residues and reduction of antimicrobial resistance, have become increasingly important during formulation development²¹.

Across all species, practical considerations, including dosing accuracy, storage stability, transportation under field conditions, ease of administration, and economic feasibility-play a decisive role in formulation design. Therefore, modern veterinary suspension development requires a multidisciplinary approach that integrates pharmaceutical sciences, veterinary pharmacology, animal physiology, and production management to achieve safe, effective, and species-appropriate therapeutic products.

3. Therapeutic Class Applications

3.1 Antibiotic Suspensions

Antibiotics constitute one of the most extensively used therapeutic classes in veterinary medicine for the prevention and treatment of bacterial infections in livestock, poultry, companion animals, and other animal species. Oral and injectable suspension formulations are widely employed because they provide flexible dosing, improve drug delivery, and facilitate administration under diverse husbandry conditions²². The choice of formulation depends on the target species, site of infection, pharmacokinetic characteristics of the drug, and practical considerations such as ease of administration and animal handling.

In cattle, the physiological characteristics of the rumen significantly influence oral drug absorption. The rumen functions as a large fermentative compartment in which many orally administered antimicrobials undergo microbial degradation before systemic absorption. Consequently, parenteral therapy is generally preferred for adult ruminants, whereas pre-ruminant calves can effectively receive oral antibiotics because the oesophageal groove allows ingested formulations to bypass the rumen and reach the abomasum directly²³. Long-acting injectable suspensions are therefore widely used in cattle for the treatment of bovine respiratory disease, metritis, mastitis, and foot infections, as they provide sustained plasma drug concentrations while minimizing handling stress and reducing dosing frequency. Injectable volume should be carefully controlled to minimize injection-site reactions and tissue damage, particularly in food-producing animals²⁴.

In poultry, antibiotics are administered predominantly through drinking water or medicated feed because these routes enable rapid treatment of large flocks with minimal labour. Water-soluble antibiotics such as amoxicillin, doxycycline, and oxytetracycline are commonly used for respiratory and gastrointestinal infections. However, formulation performance is strongly influenced by water quality, including pH, hardness, temperature, sanitizer residues, and contact time²⁵. For example, chlorine-based disinfectants such as sodium hypochlorite may inactivate β-lactam antibiotics, thereby reducing therapeutic efficacy. Injectable formulations are generally reserved for valuable breeding birds, day-old chicks, or situations requiring precise individual dosing. Furthermore, increasing global emphasis on antimicrobial stewardship has encouraged more judicious use of antibiotics in commercial poultry production²⁶.

The formulation of veterinary antibiotic suspensions presents several pharmaceutical challenges. Many antibiotics, including florfenicol and doxycycline, exhibit poor aqueous solubility, necessitating advanced formulation approaches such as nanosuspensions, micronization, salt formation, or lipid-based delivery systems to improve dissolution and bioavailability²⁷. Stability is another critical consideration, particularly for β-lactam antibiotics, which are susceptible to hydrolytic degradation in aqueous environments. Appropriate buffer systems, optimized pH, antioxidant incorporation, and suitable packaging are therefore essential for maintaining product stability throughout storage and use. In contrast, sulfonamides and trimethoprim generally demonstrate greater chemical stability under similar conditions²⁸.

Formulation characteristics should also be adapted to the intended route of administration. Oral suspensions for livestock must balance drug concentration, palatability, viscosity, and dosing volume to facilitate administration without compromising compliance. Injectable suspensions require controlled particle size distribution, appropriate rheological properties, and acceptable syringeability to ensure uniform dosing while preventing needle blockage or injection-site irritation.

Species-specific therapeutic practices further influence antibiotic selection. Third- and fourth-generation cephalosporins are widely employed in cattle for systemic infections because of their broad antimicrobial spectrum and relatively short withdrawal periods in dairy production²⁷. Tetracyclines remain first-line agents for respiratory, gastrointestinal, and ocular infections, while sulfonamides, either alone or in combination with trimethoprim, continue to provide broad-spectrum antimicrobial activity in numerous food-producing species²⁹.

In poultry, amoxicillin, doxycycline, oxytetracycline, macrolides, and enrofloxacin are commonly used to manage respiratory and enteric bacterial diseases²⁷. Companion animals frequently receive combinations such as amoxicillin-clavulanic acid for skin, respiratory, urinary, and gastrointestinal infections, whereas cephalexin, enrofloxacin, gentamicin, tetracyclines, chloramphenicol, and potentiated sulfonamides remain valuable therapeutic options depending on the causative pathogen and infection site³⁰.

Overall, the successful development of veterinary antibiotic suspensions requires an integrated formulation approach that combines pharmaceutical stability, optimized bioavailability, species-specific physiology, antimicrobial stewardship, and practical field applicability. Advances in controlled-release technologies, nanotechnology, and novel excipient systems continue to improve therapeutic performance while reducing dosing frequency and enhancing treatment compliance.

Figure 1. A schematic illustration showing advanced suspension formulation strategies (emulsions, liposomes, nanoparticles) and how they improve solubility, stability, and delivery.

 

 

Figure 2. Schematic representation of long-acting oral and injectable veterinary suspension systems.

5.1 Long-Acting Oral and Injectable Suspensions

Long-acting suspension formulations represent one of the most promising areas in veterinary drug delivery because they reduce dosing frequency, improve treatment compliance, and minimize animal handling. These advantages are particularly important in livestock production systems, where repeated restraint increases stress, labor costs, and the risk of injury.

Recent research has focused on biodegradable polymer-based depot systems, microcrystalline suspensions, lipid-based carriers, and in situ gelling formulations capable of maintaining therapeutic drug concentrations for several weeks or months. Biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA) and polycaprolactone (PCL) enable controlled drug release while gradually degrading into biocompatible metabolites. Similarly, oil-based injectable suspensions continue to demonstrate excellent performance for poorly water-soluble antibiotics, antiparasitic agents, hormones, and non-steroidal anti-inflammatory drugs⁶⁰.

Future formulation development should emphasize improved syringeability, predictable drug-release kinetics, reduced injection-site reactions, and simplified manufacturing processes to facilitate large-scale commercial production.

5.2 Nano- and Lipid-Based Drug Delivery Systems

Nanotechnology is expected to play an increasingly important role in veterinary pharmaceutical development by overcoming limitations associated with poor aqueous solubility, low oral bioavailability, and frequent dosing.

Nanostructured lipid carriers (NLCs), solid lipid nanoparticles (SLNs), polymeric nanoparticles, nanoemulsions, liposomes, and self-emulsifying drug delivery systems (SEDDS) have demonstrated significant improvements in drug loading capacity, dissolution rate, controlled release, and tissue targeting⁶¹. Lipid-based carriers additionally promote lymphatic drug transport, thereby reducing first-pass metabolism and improving systemic bioavailability⁶².

Surface-modified nanoparticles capable of targeting inflamed tissues, infectious lesions, or specific cell populations represent another promising area of investigation. Such targeted delivery systems may improve therapeutic efficacy while minimizing systemic toxicity and reducing overall drug exposure. Continued research into scalable manufacturing methods and long-term safety will be essential for translating these technologies into routine veterinary practice⁶³.

5.3 Sustainable Excipients

Environmental sustainability has become an important consideration in veterinary pharmaceutical development owing to increasing regulatory expectations and public awareness regarding ecological protection⁶⁴. Future suspension formulations are expected to incorporate biodegradable, renewable, and environmentally compatible excipients that minimize environmental persistence without compromising pharmaceutical performance.

Natural polymers including cellulose derivatives, starch, pectin, alginate, and chitosan have attracted considerable interest because of their biodegradability, excellent safety profile, and multifunctional pharmaceutical properties. Likewise, naturally derived surfactants, phospholipids, triglycerides, and other lipid-based excipients provide environmentally friendly alternatives to conventional synthetic materials⁶⁵.

5.4 Species-Specific Clinical Trials and Precision Veterinary Medicine

Future veterinary formulation development will increasingly rely on species-specific clinical trials to optimize safety, efficacy, dosage regimens, and formulation performance across diverse animal populations⁶⁶. Unlike human medicines, veterinary pharmaceuticals must accommodate substantial interspecies differences in anatomy, physiology, metabolism, feeding behaviour, and disease susceptibility⁶⁷.

Early integration of target-species pharmacokinetic, pharmacodynamic, palatability, and tolerance studies into formulation development will facilitate more accurate dose selection and improve therapeutic outcomes⁶⁸. Modern clinical trial methodologies-including adaptive trial designs, biomarker-guided assessment, computational modelling, and population pharmacokinetic analysis-offer opportunities to improve study efficiency while reducing animal use in accordance with the principles of Replacement, Reduction, and Refinement (3Rs)⁶⁹.

Future precision veterinary medicine may also incorporate artificial intelligence, digital health technologies, wearable biosensors, and real-time therapeutic monitoring to enable individualized treatment strategies tailored to specific animal species, breeds, physiological conditions, and production systems.

6. Species-Specific Formulation Considerations

The successful development of veterinary oral and injectable suspensions requires careful consideration of species-specific anatomical, physiological, metabolic, and behavioural differences. These factors significantly influence drug absorption, bioavailability, dosing accuracy, administration techniques, and therapeutic outcomes. Unlike human medicines, veterinary formulations must accommodate a wide diversity of animal species, each presenting unique pharmaceutical challenges. Therefore, formulation strategies should be tailored to the physiological and practical requirements of the target species to maximize efficacy, safety, and treatment compliance⁷⁰.

6.1 Ruminants (Cattle, Sheep, and Goats)

Ruminants present unique formulation challenges because the rumen acts as a large fermentative chamber capable of degrading many orally administered drugs before systemic absorption⁷¹. Consequently, oral suspensions intended for systemic therapy often require rumen-bypass technologies such as lipid encapsulation, enteric coating, or pH-responsive delivery systems to protect active pharmaceutical ingredients from microbial degradation.

Long-acting injectable suspensions are extensively used in cattle because they reduce handling frequency, improve treatment compliance, and maintain prolonged therapeutic drug concentrations. Formulations should exhibit appropriate viscosity, syringeability, and controlled-release characteristics while minimizing injection-site irritation and tissue residues. Large dosing volumes also require careful optimization of particle size distribution and rheological properties to ensure safe administration⁷².

6.2 Horses

Equine formulations require particular attention to palatability because horses readily reject bitter or unpleasant medications. Effective taste masking through flavouring agents, sweeteners, or microencapsulation significantly improves voluntary acceptance of oral suspensions. Formulations should also possess suitable viscosity to facilitate smooth administration using oral dosing syringes without excessive leakage or drug loss⁷³.

Injectable suspensions for horses should maintain low viscosity, uniform particle dispersion, and excellent syringeability to minimize injection-site reactions while ensuring accurate dose delivery. Since horses often exhibit rapid drug clearance, formulation strategies should also consider pharmacokinetic characteristics when designing sustained-release dosage forms⁷⁴.

6.3 Companion Animals (Dogs and Cats)

Palatability and owner compliance are critical determinants of therapeutic success in companion animals. Dogs generally accept meat- or poultry-flavoured formulations, whereas cats typically prefer fish-based flavours. Highly concentrated oral suspensions reduce dosing volume and improve acceptance, particularly in small breeds and young animals⁷⁵.

Accurate dose measurement is essential because substantial variation exists in body weight among companion animals. Ready-to-use suspensions with excellent physical stability, minimal sedimentation, and rapid redispersibility simplify administration and improve treatment adherence. Injectable formulations should minimize discomfort while maintaining appropriate drug release characteristics for chronic conditions requiring prolonged therapy.

CONCLUSION

Veterinary oral and injectable suspensions remain indispensable dosage forms for delivering therapeutic agents across a wide variety of animal species. Their versatility, dose flexibility, suitability for poorly water-soluble drugs, and potential for sustained drug release make them valuable for the treatment and prevention of infectious, parasitic, inflammatory, and nutritional disorders in companion animals, livestock, poultry, and aquaculture.

Successful formulation development requires careful consideration of species-specific physiological differences, appropriate excipient selection, particle engineering, palatability, stability, and practical administration requirements. Advances in controlled-release technologies, nanotechnology, lipid-based drug delivery systems, biodegradable polymers, and environmentally sustainable excipients have substantially expanded the capabilities of veterinary suspension formulations while improving bioavailability, therapeutic efficacy, and treatment compliance.

Despite these advances, challenges related to physical stability, chemical degradation, environmental exposure, and species-specific variability continue to influence formulation performance. Future research should therefore focus on integrating innovative pharmaceutical technologies with species-specific clinical evaluation, precision drug delivery, and sustainable manufacturing approaches. Such multidisciplinary strategies will facilitate the development of safer, more effective, and environmentally responsible veterinary suspension formulations that improve animal health, welfare, and clinical outcomes.

REFERENCES

1. Koppisetti H, Abdella S, Nakmode DD, Abid F, Afinjuomo F, Kim S, Song Y, Garg S. Unveiling the future: Opportunities in long-acting injectable drug development for veterinary care. Pharmaceutics. 2025 May 8;17(5):626.
2. Shinde V, Amsa P, Tamizharasi S, Karthikeyan D, Sivakumar T, Kosalge A. Nanosuspensions: a promising drug delivery strategy. Research Journal of Pharmacy and Technology. 2010;3(1):39-44.
3. Holm R, Lee RW, Glassco J, DiFranco N, Bao Q, Burgess DJ, Lukacova V, Alidori S. Long-acting injectable aqueous suspensions—summary from an AAPS Workshop. The AAPS Journal. 2023 Apr 28;25(3):49.
4. Quintão NL, Moffa EB, Kroier M, Goldoni RC, Bundgaard L, Jensen AL, Fernandes ES. Overview of the Current Osteoarthritis Treatment in Veterinary Medicine and Future Directions. ACS Pharmacology & Translational Science. 2026 Apr 14;9(5):1037-54.
5. Raulf MK, Raue K, Schwarz A, Petersen I, Zschiesche E, Heinau L, Strube C. A single treatment with a fluralaner injectable suspension (Bravecto® injectable) provides 1-year efficacy against Rhipicephalus sanguineus sensu lato and Ctenocephalides felis in dogs. Parasites & vectors. 2024 Oct 26;17(1):438.
6. Mao Y, Chen Y, Liu C, He X, Zheng Y, Chen X, Wang Y, Chen W, Wu Y, Shen Y, Yang H. Cefquinome sulfate oily nanosuspension designed for improving its bioavailability in the treatment of veterinary infections. International Journal of Nanomedicine. 2022 Jun 2:2535-53.
7. Schmerold I, Van Geijlswijk I, Gehring R. European regulations on the use of antibiotics in veterinary medicine. European journal of pharmaceutical sciences. 2023 Oct 1;189:106473.
8. Alfaia F, Jota Baptista C, Lozano J, Sós-Koroknai V, Hoitsy M, Madeira de Carvalho LM, Sós E. Efficacy of a New Fenbendazole Treatment Protocol against Capillaria spp. in Northern White-Breasted Hedgehog (Erinaceus roumanicus). Parasitologia. 2024 Aug 20;4(3):270-8.
9. Jacobs CC, Schnabel LV, McIlwraith CW, Blikslager AT. Non‐steroidal anti‐inflammatory drugs in equine orthopaedics. Equine veterinary journal. 2022 Jul;54(4):636-48.
10. Cabañero-Resta GJ, Sánchez-Dengra B, Ruiz-Picazo A, Bermejo M, Merino V, Gonzalez-Alvarez I, Gonzalez-Alvarez M. Pharmaceutical compounding in veterinary medicine: suspension of itraconazole. Pharmaceutics. 2024 Apr 24;16(5):576.
11. Patil A, Kadam VJ, Jadhav KR. Co-processed Pharmaceutical Excipients–A Brief Review. Research Journal of Pharmacy and Technology. 2010;3(1):50-7.
12. Killedar SG, Desai RG, Deokate PC, Adnaik RS. Evaluation of suspending properties of combined seed mucilage. Res J Pharm Tech. 2011;4(4):555-7.
13. Majed F, Wahib H, Saeed OM, Al-Joubary A, Laith N, Jassem M. Preparation and Evaluation of Mebendazole 5% Antiparasitic Suspension for Veterinary Use. Iraqi Journal of Industrial Research. 2022 Oct 20;9(2):243-7.
14. Debbarma R, Singh SK, Ngasotter S, Choudhury TG, Biswas P, Waikhom G. Characterization and evaluation of Moringa oleifera seed powder as a flocculating agent in biofloc culture of Clarias magur catfish. Scientific Reports. 2026 Jun 17.
15. Jameel Ahmed Mulla, Sarasija Suresh, Imtiyaz Ahmed Khazi. Formulation, Characterization and in vitro Evaluation of Methotrexate Solid Lipid Nanoparticles. Research J. Pharm. and Tech.2 (4): Oct.-Dec. 2009; Page 685-689.
16. Nikita N. Chauhan, Niraj V. Patel, Shakti J. Suthar, Jayvadan K. Patel, Manish P. Patel. Micronization of BCS Class–II Drugs by Various Approaches for Solubility Enhancement – A Review. Research J. Pharm. and Tech. 5(8): August 2012; Page 999-1005.
17. Patel SR, Shah DP. A review on nanocrystals drug delivery system. Research Journal of Pharmacy and Technology. 2015 May 1;8(5):647.
18. Mostafa Abdalhamed A, Zeedan GS, Ahmed Arafa A, Shafeek Ibrahim E, Sedky D, Abdel nabey Hafez A. Detection of Methicillin‐Resistant Staphylococcus aureus in Clinical and Subclinical Mastitis in Ruminants and Studying the Effect of Novel Green Synthetized Nanoparticles as One of the Alternative Treatments. Veterinary Medicine International. 2022;2022(1):6309984.
19. Martinez MN, Papich MG, Fahmy R. Impact of gastrointestinal differences in veterinary species on the oral drug solubility, in vivo dissolution, and formulation of veterinary therapeutics. ADMET and DMPK. 2022 Feb 14;10(1):1-25.
20. Sharma A, Sharma PK, Kompella UB. Lotilaner for demodex blepharitis: the journey from veterinary use to human medicine. Journal of Ocular Pharmacology and Therapeutics. 2025 May 1;41(4):173-86.
21. Ayinde WB, Ikumi D, Basitere M. Veterinary antibiotic removal from poultry slaughterhouse (PSH) wastewater: a mini-review of environmental nanoremediation techniques. Environmental Technology Reviews. 2025 Dec 31;14(1):359-70.
22. Ghimpețeanu OM, Pogurschi EN, Popa DC, Dragomir N, Drăgotoiu T, Mihai OD, Petcu CD. Antibiotic use in livestock and residues in food—A public health threat: A review. Foods. 2022 May 16;11(10):1430.
23. Hooper SE, Korte SW, Giguère S, Fales WH, Davis JL, Dixon LW. Pharmacokinetics of ceftiofur crystalline-free acid in clinically healthy dogs (Canis lupus familiaris). Journal of the American Association for Laboratory Animal Science. 2016 Mar 1;55(2):224-9.
24. Selimov R, Goncharova E, Koriakovtsev P, Gabidullina D, Karsakova J, Kozlov S, Komarov A, Engasheva E, Engashev S. Comparative pharmacokinetics of florfenicol in heifers after intramuscular and subcutaneous administration. Journal of Veterinary Pharmacology and Therapeutics. 2023 May;46(3):177-84.
25. Kotb S, Ahmed M, Hassan D, Soltan E. Stability of antibiotics in drinking water: An advanced approach towards the impacts of water quality parameters on doxycycline bioavailability. Journal of Advanced Veterinary and Animal Research. 2019 Sep 9;6(4):438.
26. Xu C, Kong L, Gao H, Cheng X, Wang X. A review of current bacterial resistance to antibiotics in food animals. Frontiers in microbiology. 2022 May 12;13:822689.
27. Hahne F, Müller C, Yalman S, Meißner J, Kietzmann M, Hamscher G. Stability of important veterinary antibiotics Amoxicillin, Sulfadiazine, and Trimethoprim in practice-relevant model solutions. Antibiotics. 2023 Jan 19;12(2):214.
28. Abonashey SG, Hassan HA, Shalaby MA, Fouad AG, Mobarez E, El-Banna HA. Formulation, pharmacokinetics, and antibacterial activity of florfenicol-loaded niosome. Drug Delivery and Translational Research. 2024 Apr;14(4):1077-92.
29. De Briyne N, Atkinson J, Borriello SP, Pokludová L. Antibiotics used most commonly to treat animals in Europe. Veterinary Record. 2014 Oct;175(13):325-.
30. Common Antibiotics for Dogs and Cats - Wedgewood Pharmacy n.d. https://www.wedgewood.com/blog/common-antibiotics-for-dogs-and-cats/.
31. Antibiotic in the form of a water-soluble powder for veterinary and human use 2005.
32. Abou-Jaoudeh C, Andary J, Abou-Khalil R. Antibiotic residues in poultry products and bacterial resistance: A review in developing countries. Journal of Infection and Public Health. 2024 Dec 1;17(12):102592.
33. Macedo LO, Silva SS, Alves LC, Carvalho GA, Ramos RA. An overview of anthelmintic resistance in domestic ruminants in Brazil. Ruminants. 2023 Aug 29;3(3):214-32.
34. Sulik M, Antoszczak M, Huczyński A, Steverding D. Antiparasitic activity of ivermectin: Four decades of research into a “wonder drug”. European Journal of Medicinal Chemistry. 2023 Dec 5;261:115838.
35. Antiparasitic Resistance | FDA n.d. https://www.fda.gov/animal-veterinary/safety-health/antiparasitic-resistance.
36. Shi Y, Lu A, Wang X, Belhadj Z, Wang J, Zhang Q. A review of existing strategies for designing long-acting parenteral formulations: focus on underlying mechanisms, and future perspectives. Acta Pharmaceutica Sinica B. 2021 Aug 1;11(8):2396-415.
37. Gao P, Nie X, Zou M, Shi Y, Cheng G. Recent advances in materials for extended-release antibiotic delivery system. The Journal of antibiotics. 2011 Sep;64(9):625-34.
38. Corticosteroids in Animals - Pharmacology - MSD Veterinary Manual n.d. https://www.msdvetmanual.com/pharmacology/inflammation/corticosteroids-in-animals.
39. Lees P, Landoni MF, Giraudel J, Toutain PL. Pharmacodynamics and pharmacokinetics of nonsteroidal anti‐inflammatory drugs in species of veterinary interest. Journal of veterinary pharmacology and therapeutics. 2004 Dec;27(6):479-90.
40. Gober M, Hillier A. Perception and usage of short-term prednisone and prednisolone in dogs. BMC veterinary research. 2023 Jul 24;19(1):91.
41. Sparkes AH, Heiene R, Lascelles BD, Malik R, Real L, Robertson S, Scherk M, Taylor P. ISFM and AAFP consensus guidelines: long-term use of NSAIDs in cats. Journal of feline medicine and surgery. 2010 Jul;12(7):521-38.
42. KuKanich B. A review of selected systemic antifungal drugs for use in dogs and cats. Vet Med. 2008 Jan 1;103(1):41-50.
43. Hanzlicek A. Antifungal Therapy in Small Animal Medicine n.d.
44. Finno CJ. Veterinary pet supplements and nutraceuticals. Nutrition today. 2020 Mar 1;55(2):97-101.
45. Saiyed MA, Joshi RS, Savaliya FP, Patel AB, Mishra RK, Bhagora NJ. Study on inclusion of probiotic, prebiotic and its combination in broiler diet and their effect on carcass characteristics and economics of commercial broilers. Veterinary World. 2015 Feb 25;8(2):225.
46. Sadozai H, Saeidi D. Recent developments in liposome‐based veterinary therapeutics. International Scholarly Research Notices. 2013;2013(1):167521.
47. Carvalho SG, Araujo VH, Dos Santos AM, Duarte JL, Silvestre AL, Fonseca-Santos B, Villanova JC, Gremião MP, Chorilli M. Advances and challenges in nanocarriers and nanomedicines for veterinary application. International journal of pharmaceutics. 2020 Apr 30;580:119214.
48. Youssef FS, El-Banna HA, Elzorba HY, Galal AM. Application of some nanoparticles in the field of veterinary medicine. International journal of veterinary science and medicine. 2019 Jan 2;7(1):78-93.
49. Danchuk O, Levchenko A, da Silva Mesquita R, Danchuk V, Cengiz S, Cengiz M, Grafov A. Meeting contemporary challenges: development of nanomaterials for veterinary medicine. Pharmaceutics. 2023 Sep 15;15(9):2326.
50. Sorn S, Hara-Yamamura H, Vet S, Xiao M, Hoek EM, Honda R. Biological treatment of perfluorooctanesulfonic acid (PFOS) using microbial capsules of a polysulfone membrane. Chemosphere. 2023 Jul 1;329:138585.
51. Kumar S, Kumar A, Kumar N, Singh P, Singh TU, Singh BR, Gupta PK, Thakur VK. In vivo therapeutic efficacy of Curcuma longa extract loaded ethosomes on wound healing. Veterinary research communications. 2022 Dec;46(4):1033-49.
52. Rhee CH, Lee HS, Yun HJ, Lee GH, Kim SJ, Song S, Lee MH, Her M, Jeong W. Chemical stability of active ingredients in diluted veterinary disinfectant solutions under simulated storage conditions. Frontiers in Chemistry. 2023 Jun 16;11:1204477.
53. Rodjan P, Sangkanu S, Mitsuwan W, Pongpom M, Saengsawang P, Tedja I, Lamai J, Pruksaphon K, Jeenkeawpieam J. Antibacterial and antivirulence factor activities of protein hydrolysates from Phatthalung Sangyod rice (Oryza sativa L.) seeds against zoonotic and foodborne pathogens. Veterinary World. 2023 Oct 7;16(10):2002.
54. Verma AK, Singh A, Singh AK, Maurya PS, Jaiswal V, Sachan V. Precision veterinary therapeutics through nanomedicine: Platforms, applications, and One Health implications. Next Research. 2026 Apr 14:101747.
55. Lysak OM, Peleno RA, Tymoshenko МV. The assessment of the stability of the disinfectant “DezA Ultra” and its ready-made solutions during the expected shelf life. Scientific Messenger of LNU of Veterinary Medicine and Biotechnologies. Series: Veterinary Sciences. 2025 Jun 18;27(118):149-56.
56. Sebbag L, Barbosa SF, Oriá AP. Tacrolimus and hyaluronate therapy enhance tear film stability in canine evaporative dry eye disease. Veterinary Ophthalmology. 2026 Mar;29(2):e70042.
57. Zuccari G, Alfei S. Development of phytochemical delivery systems by nano-suspension and nano-emulsion techniques. International Journal of Molecular Sciences. 2023 Jun 6;24(12):9824.
58. Khademi E, Nemati F, Piri‐Gharaghie T. Alginate‐Based Microencapsulation of Saccharomyces Boulardii for Enhanced In Vitro Stability in Poultry Sector: A Novel Strategy for Probiotic Delivery. Veterinary Medicine and Science. 2026 Mar;12(2):e70841.
59. Huang Y, Patil CD, Arte KS, Liu J, Nie H, Zhou QT, Qu LL. Recent Advances in Particle Design for High-Concentration Protein Suspension Injectables. Pharmaceutics. 2026 Apr 7;18(4):450.
60. Turaga S, Yong D, Valicherla GR, Leary S, Witham S, Levinson B, Rohan L, Patel SK. An Extended-Release Injectable Suspension of Meloxicam for Pain Management in Veterinary Applications. Journal of Pharmaceutical Innovation. 2026 Aug;21(4):370.
61. Güncüm E, Erdem P. Nanoparticle-Based Formulations of Antiparasitic Drugs: Advantages, Limitations, and Future Perspectives. Veteriner Farmakoloji ve Toksikoloji Derneği Bülteni. 2026 Mar 3;17(2026).
62. Singh A, Maheshwari S, Prajapati BG, Singh S. Unlocking the potential of lyophilization as a stability improvement strategy for lipid-based drug delivery system: A review. Drying Technology. 2026 May 1:1-27.
63. Zhang Y, Zhou S, Li S, Zheng C, Chen X, Gu Z. Development and Characterization of a Curcumin‐Loaded Lipid‐Based Solution With Improved Pharmacokinetics and Hepatoprotective Efficacy in Grass Carp. Aquaculture, Fish and Fisheries. 2026 Apr;6(2):e70240.
64. Taylor A, Ketolainen J, Paulsson M, Autenrieth J, Lindh J, Rönnberg H. Reusable gelatin-based inks for 3D printing of veterinary gabapentin tablets: a sustainable approach. Frontiers in Veterinary Science. 2026 May 13;13:1835903.
65. Zahn I, Coleman AE, Elder DL, Zhang C, Arnold RD, Papich MG. The effect of excipients on the oral absorption of pimobendan in healthy dogs. Journal of Veterinary Cardiology. 2026 Feb 1;63:36-46.
66. Babaei M, Mehdikhani M, Yilgor P, Oto C, Poursamar SA, Rafienia M. Personalized care in veterinary medicine: exploring the potential of additive manufacturing for patient-specific solutions. Emergent Materials. 2026 Apr;9(4):80.
67. Miranda-Muñoz KA, Tsai T, Powell JG, Almodovar J. Advances in veterinary drug and vaccine delivery: from conventional delivery methods to innovative transdermal approaches. Drug Delivery and Translational Research. 2026 Apr 20:1-32.
68. Pițuru MT, Apetroaei-Leucă MM, Ștefan G, Șonea C, Tăpăloagă D, Velescu BȘ, Arsene AL, Udeanu DI, Nedea MI, Vlăgioiu C. Topical Anti-Inflammatory Therapies in Veterinary Medicine: Advancing Animal Health Through a One Health Approach. Animals: an Open Access Journal from MDPI. 2026 Apr 18;16(8):1252.
69. Cagle AL, Limberg AK, Anup A, La Croix AE, Hixon KR. Advancing the 3Rs in bone tissue engineering: emerging in vitro, in silico, and refined in vivo strategies. Frontiers in Physiology. 2026 May 11;17:1811508.
70. Vlăgioiu AD, Diaconescu A, Brăslașu D, Ionașcu I. From Concept to Cure: What our Drug Preparation Laboratory Achieved So Far. Bulletin of the University of Agricultural Sciences & Veterinary Medicine Cluj-Napoca. Veterinary Medicine. 2026 May 1;83(1):62.
71. Čudina N, Marić M, Chambers L, Vidalinc M, Aagaard AK, Balado J, Bratić P, Ganter M, Grønborg AH, Şenyüz HH, Spezzigu A. Development of the European Veterinary Medicines Gaps and Needs Compass for Sheep and Goats Based on Online Survey and Expert Knowledge Elicitation. Veterinary sciences. 2026 Mar 21;13(3):297.
72. Berdikulov M, Alan Webb JE, Aknazarov S, Shynybayev K, Sansyzbay A, Taranov D, Yessimsiitovaa Z, Lessova Z. Role of cross-border epizootic risks in ensuring veterinary safety and sustainable livestock development in Central Asia. Caspian Journal of Environmental Sciences. 2026 Apr 1;24(2):531-47.
73. Pfeifle RL, Hart KA, Berghaus LJ, Coleman MC. Effects of Nebulized Alpha-2 Macroglobulin in Horses with Lower Airway Inflammation. Journal of Equine Veterinary Science. 2026 Jul 3:106076.
74. Tyson KN, Couetil LL, Ivester KM, Murray L, Mukhopadhyay A, Marmolejo JF, Jannasch A. A randomized, masked, crossover, clinical trial of the efficacy and safety of nebulized albuterol sulfate and dexamethasone sodium phosphate in asthmatic horses. Journal of Veterinary Internal Medicine. 2026 Mar;40(2):aalag030.
75. Afnani DA, Tyasningsih W, Permatasari DA, Ugbo EN, Aydin A, Effendi MH, Budiastuti B. Potential risks to public health based on molecular evidence of the mecA gene encoding Methicillin-Resistant Staphylococcus aureus (MRSA) isolated from Cats swabbed in Veterinary Clinics and Hospitals in Surabaya, Indonesia.